Tectonic Advisors LLC Purchases 49,737 Shares of Pfizer Inc. $PFE

Tectonic Advisors LLC increased its position in Pfizer Inc. (NYSE:PFE) by 16.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 348,424 shares of the biopharmaceutical company’s stock after buying an additional 49,737 shares during the quarter. Tectonic Advisors LLC’s holdings in Pfizer were worth $8,878,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in PFE. Capital Advisory Group Advisory Services LLC boosted its stake in shares of Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 388 shares in the last quarter. Citizens National Bank Trust Department lifted its stake in Pfizer by 0.9% in the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after purchasing an additional 395 shares during the last quarter. Peak Asset Management LLC grew its stake in shares of Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after buying an additional 402 shares during the last quarter. Able Wealth Management LLC increased its holdings in shares of Pfizer by 2.0% in the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock worth $512,000 after buying an additional 413 shares during the period. Finally, Boltwood Capital Management lifted its stake in shares of Pfizer by 0.7% in the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock valued at $1,485,000 after acquiring an additional 420 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PFE. Cowen restated a “hold” rating on shares of Pfizer in a research report on Tuesday. Bank of America decreased their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Citigroup began coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.06.

Pfizer Stock Performance

NYSE:PFE opened at $24.90 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm’s fifty day simple moving average is $25.17 and its 200 day simple moving average is $24.90. The stock has a market cap of $141.57 billion, a P/E ratio of 14.48 and a beta of 0.47. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Zacks raised near-term quarterly EPS outlooks for Q2 2026 and Q2 2027 (small bumps to $0.66 and $0.62 respectively), suggesting some stabilization in earnings momentum. (MarketBeat summary)
• Positive Sentiment: Analysts/industry reports show Pfizer leading drugmakers planning price increases on many branded medications — this could support revenue and margins if implemented. Read More.
• Positive Sentiment: Several value-oriented pieces argue Wall Street has “given up” on Pfizer and that the company looks attractively valued given stabilized revenue and a rebuilding pipeline — these narratives can attract long-term/income investors. Read More.
• Neutral Sentiment: Multiple retail-investor columns (The Motley Fool, NAI500, Kalkine) debate whether Pfizer under $25–$30 is a buy — useful context for retail flows but not an immediate catalyst. Read More. · Read More. · Read More.
• Negative Sentiment: Zacks trimmed its Q4 2027 EPS estimate slightly (to $0.70 from $0.71) and previously cut Q4 2025 estimates; those downward revisions are direct near-term negatives for earnings expectations. (MarketBeat summary)
• Negative Sentiment: TD Cowen maintained a Hold rating for PFE — a lack of upward revisions from a respected shop can cap upside and reinforce cautious positioning. Read More.
• Negative Sentiment: Coverage pieces noting Pfizer’s multi-year pullback from pandemic highs and underperformance vs. the market underscore investor wariness and explain continued selling pressure. Read More.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.